European cancer biomarker market is projected to grow at CAGR of 11.6% during the forecast period. The Europe is considered to be one of the dominating regions in the cancer biomarker market as it has a high healthcare expenditure and infrastructure. Major factor contributing to the cancer biomarker market are high prevalence of cancer, high per capita healthcare expenditure and high awareness towards cancer in the region. Unhealthy lifestyle such as smoking, consumption of drugs and alcohol in country are the major factors for the prevalence of cancer among men and women. Government’s initiatives, programs and funding for the cancer related programs are also contributing in the growth of cancer biomarker market in the region. In Europe, several key players are present which are driving the cancer biomarker market such as Agendia N.V., bioMérieux S.A., Novartis AG and QIAGEN N.V.

Request a Free Sample of our European Cancer Biomarker Market: https://www.omrglobal.com/request-sample/european-cancer-biomarker-market

In men, prostate cancer is the most common type of disease in Northern, Western and Southern European nations, while lung cancer is the most commonly diagnosed in Central and Eastern Europe. Lung growth is the main source of cancer for deaths among men in every European nation, while breast cancer is most common in women. Activities such as smoking, alcohol; consumption, inactivity, inadequate diet and other sources are some of the factors responsible for cancer, which creates scopes for the European cancer biomarker growth during the forecast period.

A full Report of European Cancer Biomarker Market is Available at: https://www.omrglobal.com/industry-reports/european-cancer-biomarker-market

According to the International Association for the study of Lung cancer, the European teenager have a high susceptibility of smoking as that of rest of the world. This will eventually increase the incidence of lung cancer. In future lung cancer incidences and deaths will eventually rise in the European region. Hence the European cancer biomarker market will also increase.

European Cancer Biomarker Market Segmentation

By Biomarker Type

• Genetic Biomarker
• Protein Biomarker

By Cancer Type

• Lung Cancer
• Prostate Cancer
• Breast Cancer
• Colorectal Cancer
• Cervical Cancer
• Other
By Applications

• Drug Discovery and Development
• Diagnosis
• Risk Assessment
• Prognostics

By Profiling Technology

• Omics Technology
• Immunoassays
• Cytogenetics
• Bioinformatics

Regional Analysis

• UK
• Germany
• Italy
• France
• Spain
• Rest of Europe

Company Profiles

• Abbott laboratories Inc.
• Astellas Pharma Inc.
• Becton, Dickson and Co.
• Bio-Rad Laboratories, Inc.
• Danaher Corp.
• F. Hoffmann-La Roche Ltd.
• Merck and Co., Inc.
• Novartis AG
• Pfizer Inc.
• QIAGEN GmbH
• Thermo Fisher Scientific Inc.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/european-cancer-biomarker-market

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
For More Information, Visit Orion Market Research
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +1 646-755-7667, +91 7803040404